Evidence map›Paper›PMID 24391880›Full record

Trial reportPloS one2013

MLVA as a tool for public health surveillance of human Salmonella Typhimurium: prospective study in Belgium and evaluation of MLVA loci stability.

Véronique Wuyts, Wesley Mattheus, Guillaume De Laminne de Bex, Christa Wildemauwe, Nancy H C Roosens, Kathleen Marchal, Sigrid C J De Keersmaecker, Sophie Bertrand

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Genetic diversity and delineation ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Observational
  6. Multidrug-ResistantInternational journal of genomics · 2019
    Article
  7. Review
  8. Rise and fall of outbreak-specific clone inside endemic pulsotype ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Phenotypic and Genotypic Eligible Methods forFrontiers in microbiology · 2017
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Véronique WuytsDepartment of Microbial and Molecular Systems, KU Leuven, Leuven, Belgium ; Platform Biotechnology and Molecular Biology, Scientific Institute of Public Health (WIVISP), Brussels, Belgium.
Wesley MattheusNational Reference Centre for Salmonella and Shigella, Bacterial Diseases Division, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Guillaume De Laminne de BexNational Reference Centre for Salmonella and Shigella, Bacterial Diseases Division, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Christa WildemauweNational Reference Centre for Salmonella and Shigella, Bacterial Diseases Division, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Nancy H C RoosensPlatform Biotechnology and Molecular Biology, Scientific Institute of Public Health (WIVISP), Brussels, Belgium.
Kathleen MarchalDepartment of Microbial and Molecular Systems, KU Leuven, Leuven, Belgium ; Department of Plant Biotechnology and Bioinformatics, Ghent University, Gent, Belgium ; Department of Information Technology, Ghent University, IMinds, Gent, Belgium.
Sigrid C J De KeersmaeckerPlatform Biotechnology and Molecular Biology, Scientific Institute of Public Health (WIVISP), Brussels, Belgium.
Sophie BertrandNational Reference Centre for Salmonella and Shigella, Bacterial Diseases Division, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surveillance of Salmonella enterica subsp. enterica serovar Typhimurium (S. Typhimurium) is generally considered to benefit from molecular techniques like multiple-locus variable-number of tandem repeats analysis (MLVA), which allow earlier detection and confinement of outbreaks. Here, a surveillance study, including phage typing, antimicrobial susceptibility testing and the in Europe most commonly used 5-loci MLVA on 1,420 S. Typhimurium isolates collected between 2010 and 2012 in Belgium, was used to evaluate the added value of MLVA for public health surveillance. Phage types DT193, DT195, DT120, DT104, DT12 and U302 dominate the Belgian S. Typhimurium population. A combined resistance to ampicillin, streptomycin, sulphonamides and tetracycline (ASSuT) with or without additional resistances was observed for 42.5% of the isolates. 414 different MLVA profiles were detected, of which 14 frequent profiles included 44.4% of the S. Typhimurium population. During a serial passage experiment on selected isolates to investigate the in vitro stability of the 5 MLVA loci, variations over time were observed for loci STTR6, STTR10, STTR5 and STTR9. This study demonstrates that MLVA improves public health surveillance of S. Typhimurium. However, the 5-loci MLVA should be complemented with other subtyping methods for investigation of possible outbreaks with frequent MLVA profiles. Also, variability in these MLVA loci should be taken into account when investigating extended outbreaks and studying dynamics over longer periods.

Indexed as

Public Health SurveillanceBacterial Typing TechniquesBelgiumDisease OutbreaksHumansMinisatellite RepeatsProspective StudiesSalmonella InfectionsSalmonella typhimurium

Identifiers

PMID24391880
PMCPMC3877154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.